A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Latest Information Update: 03 Jun 2025
At a glance
- Drugs KSI 101 (Primary)
- Indications Ocular inflammation
- Focus Registrational; Therapeutic Use
- Acronyms PINNACLE
- Sponsors Kodiak Sciences
Most Recent Events
- 27 Mar 2025 According to Kodiak Sciences media release, company announced that the Phase 2b/3 trial has been initiated
- 27 Mar 2025 According to Kodiak Sciences media release, Status changed from planning to not yet recruiting.
- 25 May 2024 New trial record